Illumina, INC.: management transactions · United States · SEC (Form 4)

About Illumina, INC.

Illumina, Inc. is a leading genomics technology company listed on the Nasdaq (United States) under the ticker ILMN. Founded in 1998 in San Diego, California, the company built its franchise around DNA sequencing, microarray technologies, and related software and consumables. Its worldwide headquarters remain in San Diego, and its commercial footprint is global, with operations and customer support across the Americas, Europe, and Asia-Pacific. ([illumina.com](https://www.illumina.com/company/about-us.html?utm_source=openai)) Illumina’s business model is centered on selling sequencing platforms, reagents, consumables, analysis tools, and services to academic research institutions, pharmaceutical companies, biotech firms, hospitals, and molecular diagnostics players. The company is historically tied to sequencing-by-synthesis (SBS), a technology that became an industry standard, and it continues to invest in higher throughput, better accuracy, and lower cost per sample. That technology base has given Illumina a strong competitive position in high-throughput sequencing, although the market remains competitive, including from long-read sequencing specialists and other emerging platforms. ([illumina.com](https://www.illumina.com/content/dam/illumina-marketing/documents/company/illumina-corporate-fact-sheet-072214.pdf)) Illumina’s portfolio spans sequencing instruments, library-prep kits, chemistry, and interpretation software. Next-generation systems such as NovaSeq X and software products like DRAGEN are central to its strategy, alongside a growing focus on clinical genomics, precision oncology, translational research, and multiomics workflows. The company has also expanded its clinical oncology offering, including broader reimbursement for TSO Comprehensive after regulatory approval, which improves accessibility for clinicians and patients. ([investor.illumina.com](https://investor.illumina.com/news/press-release-details/2026/Illumina-unveils-roadmap-of-groundbreaking-NovaSeq-X-advancements-in-data-quality-output-speed-and-flexibility/default.aspx?utm_source=openai)) Geographically, Illumina is a U.S.-based company with a truly international revenue and operating profile. It serves customers in more than 160 countries and maintains offices and commercial teams across multiple regions. For French-speaking investors, this matters because it diversifies exposure beyond one market, while still leaving the company sensitive to laboratory capex cycles, public health budgets, and local regulatory developments. ([illumina.com](https://www.illumina.com/company/about-us.html?utm_source=openai)) Recent highlights underscore a renewed innovation push. Illumina reported full-year 2025 results on February 5, 2026, and first-quarter 2026 results on April 30, 2026, including Q1 revenue of $1.09 billion and a new $1.5 billion share repurchase authorization. In 2025 and 2026, the company also announced advances around oncology, 5-base solutions, DRAGEN v4.5, NovaSeq X improvements, and collaborations aimed at AI-enabled drug discovery. Taken together, these moves indicate a strategy focused on product innovation, operating leverage, and broader clinical adoption. ([investor.illumina.com](https://investor.illumina.com/news/press-release-details/2026/Illumina-Reports-Financial-Results-for-Fourth-Quarter-and-Fiscal-Year-2025/default.aspx))